Key Developments For Aurobindo Pharma Ltd
Aurobindo Pharma Ltd (ARBN.BO) (Bombay Stock Exchange)
Aurobindo Pharma Limited's Board Recommends Final Dividend
Aurobindo Pharma Limited announced that it has recommended the final dividend at 30% (INR1.50 per share of INR5 each) on the equity share capital of the Company for the year 2008-2009.
Aurobindo Pharma Limited Receives Final Approval For Perindopril Erbumine Tablets
Aurobindo Pharma Limited announced that it's tentatively approved ANDA for Perindopril Erbumine Tablets 2mg,4mg and 8mg has received the final approval from the US Food and Drug Administration.
Aurobindo Pharma Limited Receives Final Approval For Cefotaxime For Injection USP
Aurobindo Pharma Limited announced that the Company has received final approval from the US Food And Drug Administration for 2 ANDAs namely Cefotaxime for Injection USP 500mg, 1g, 2g and Cefotaxime for Injection USP 10g pharmacy bulk pack.
Aurobindo Pharma Limited Receives Final Approval For Lamotrigine Tablets From USFDA
Aurobindo Pharma Limited announced that it has received the final approval for Lamotrigine Tablets (Chewable, Dispersible) 5mg and 25 mg from the US Food And Drug Administration.
Aurobindo Pharma Limited Announces Allotment Of Shares On Conversion Of FCCBs
Aurobindo Pharma Limited announced that it has allotted 83,121 Equity Shares of INR 5 each for cash at a premium of INR 517.036 by conversion of Bonds worth USD1,000,000 in terms of the offer document to the FCCB holders. The conversion price of INR 522.036 per share with a fixed rate of exchange on conversion at INR 43.3925 per $1.
